Natera, Inc. (NASDAQ:NTRA) Shares Sold by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP reduced its holdings in Natera, Inc. (NASDAQ:NTRA) by 82.5% during the 4th quarter, Holdings Channel reports. The fund owned 31,471 shares of the medical research company’s stock after selling 147,957 shares during the period. ExodusPoint Capital Management LP’s holdings in Natera were worth $4,982,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Natera by 7.7% during the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company’s stock valued at $1,949,697,000 after buying an additional 879,463 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Natera by 43.7% during the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company’s stock worth $1,060,836,000 after buying an additional 2,036,396 shares during the period. Wellington Management Group LLP lifted its stake in Natera by 15.7% during the fourth quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company’s stock worth $512,898,000 after purchasing an additional 439,778 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Natera by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company’s stock valued at $355,809,000 after acquiring an additional 142,201 shares during the period. Finally, Franklin Resources Inc. lifted its position in shares of Natera by 40.0% during the fourth quarter. Franklin Resources Inc. now owns 1,538,875 shares of the medical research company’s stock worth $243,604,000 after purchasing an additional 439,540 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on NTRA shares. Piper Sandler boosted their price target on shares of Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, March 19th. Guggenheim lifted their price target on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Barclays assumed coverage on shares of Natera in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $178.12.

Natera Stock Down 3.5 %

NTRA stock opened at $133.87 on Friday. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a fifty day moving average of $156.81 and a 200-day moving average of $151.40. The stock has a market capitalization of $18.10 billion, a PE ratio of -76.06 and a beta of 1.80.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 24,861 shares of Natera stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the completion of the sale, the insider now directly owns 140,684 shares in the company, valued at approximately $23,208,639.48. This trade represents a 15.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 25,931 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07. Following the completion of the sale, the chief financial officer now owns 109,665 shares in the company, valued at approximately $18,091,435.05. This represents a 19.12 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 325,922 shares of company stock worth $51,603,664. 7.60% of the stock is owned by corporate insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.